Management of Acute Myeloid Leukemia (AML) in Older Patients.
Management of Acute Myeloid Leukemia (AML) in Older Patients.
复制标题
DOI：
10.1007/s11912-020-00964-1
复制
发表时间：
2020-07-28
影响因子：
4.7
通讯作者：
Loh KP
中科院分区：
文献类型：
--
作者：
Abdallah M;Xie Z;Ready A;Manogna D;Mendler JH;Loh KP
急性髓性白血病（AML）的治疗领域在过去几年中迅速发展。这些变化对临床预后较差的老年人（≥60岁）的护理有一些影响。我们回顾了老年人的决策，重点是患者和疾病相关因素。然后，我们根据假设的临床情况总结当前的治疗方案，包括最近批准的多种治疗方法。代替使用实足年龄来确定健康，我们强调使用老年评估标准化健康评估的重要性。接下来，我们回顾前期强化和低强度治疗方案。我们专注于多种新批准的药物，包括venetoclax、midostoin、CPX-351、gemtuzumab、glasdegib、enasidenib和ivosidenib，以及它们的特定适应症。最后，我们简要讨论老年AML患者的支持性护理。老年AML患者的预后仍然很差；幸运的是，有许多新的有希望的治疗方案。基于患者和疾病特异性因素的个性化治疗计划对于老年AML患者的护理至关重要。
The acute myeloid leukemia (AML) treatment landscape has rapidly evolved over the past few years. These changes have several implications for the care of older adults (≥ 60 years), who have inferior clinical outcomes. We review decision-making in older adults, focusing on patient- and disease-related factors. We then summarize current treatment options, including multiple recently approved therapies, based on hypothetical clinical scenarios. In lieu of using chronological age to determine fitness, we highlight the importance of standardized fitness assessments using geriatric assessments. Next, we review intensive and lower-intensity treatment options in the upfront setting. We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. Lastly, we briefly discuss supportive care of older adults with AML. Outcomes of older adults with AML remain poor; fortunately, there are many new promising treatment options. Personalized treatment plans based on patient- and disease-specific factors are essential to the care of older adults with AML.
登录
查看更多内容
影响因子：
2.7
作者：
Alibhai SM;O'Neill S;Fisher-Schlombs K;Breunis H;Brandwein JM;Timilshina N;Tomlinson GA;Klepin HD;Culos-Reed SN
通讯作者：
Culos-Reed SN
影响因子：
3.6
作者：
Crawford, Rebecca;Sully, Kate;Gater, Adam
通讯作者：
Gater, Adam
影响因子：
6.2
作者：
Burnett, Alan K.;Milligan, Donald;Wheatley, Keith
通讯作者：
Wheatley, Keith
影响因子：
45.3
作者：
Burnett, Alan K.;Russell, Nigel H.;Milligan, Donald
通讯作者：
Milligan, Donald
影响因子：
45.3
作者：
Burnett, Alan K.;Hills, Robert K.;Wheatley, Keith
通讯作者：
Wheatley, Keith